Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. (Q42914716)
Jump to navigation
Jump to search
scientific article published on 7 September 2010
Language | Label | Description | Also known as |
---|---|---|---|
English | Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. |
scientific article published on 7 September 2010 |
Statements
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial (English)
Philippe Moreau
Thierry Facon
Lotfi Benboubker
Gerald Marit
Pascal Lenain
Jean-Luc Harousseau
Mohamad Mohty
Michel Attal
Claire Mathiot
Marie-Odile Petillon
Mauricette Michallet
Frédéric Maloisel
Philippe Casassus
Denis Caillot
Cyrille Hulin
Hervé Maisonneuve
7 September 2010